Diagnostic and Prognostic Value of Three microRNAs in Environmental Asbestiform Fibers-Associated Malignant Mesothelioma
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patients and Samples Collection
2.2. RNA Isolation and RT
2.3. Droplet Digital PCR
2.4. In Silico Analysis
2.5. Statistical Analysis
3. Results
3.1. Evaluation of miRNA Expression Profiling Using ddPCR
3.2. In Silico Interaction between miRNAs and Main Genes Involved in Malignant Mesothelioma
3.3. In Silico Interaction between miRNAs and Asbestos Exposure, Tumor Stage, and Patient Survival
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- Baumann, F.; Ambrosi, J.-P.; Carbone, M. Asbestos is not just asbestos: An unrecognised health hazard. Lancet Oncol. 2013, 14, 576–578. [Google Scholar] [CrossRef]
- Filetti, V.; Vitale, E.; Broggi, G.; Hagnäs, M.P.; Candido, S.; Spina, A.; Lombardo, C. Update of in vitro, in vivo and ex vivo fluoro-edenite effects on malignant mesothelioma: A systematic review. Biomed. Rep. 2020, 13, 60. [Google Scholar] [CrossRef]
- Rapisarda, V.; Salemi, R.; Marconi, A.; Loreto, C.; Graziano, A.C.E.; Cardile, V.; Basile, M.S.; Candido, S.; Falzone, L.; Spandidos, D.A.; et al. Fluoro-edenite induces fibulin-3 overexpression in non-malignant human mesothelial cells. Oncol. Lett. 2016, 12, 3363–3367. [Google Scholar] [CrossRef] [Green Version]
- Falzone, L.; Marconi, A.; Loreto, C.; Franco, S.; Spandidos, D.A.; Libra, M. Occupational exposure to carcinogens: Benzene, pesticides and fibers. Mol. Med. Rep. 2016, 14, 4467–4474. [Google Scholar] [CrossRef] [Green Version]
- Soffritti, M.; Minardi, F.; Bua, L.; Degli Esposti, D.; Belpoggi, F. First experimental evidence of peritoneal and pleural mesotheliomas induced by fluoro-edenite fibres present in Etnean volcanic material from Biancavilla (Sicily, Italy). Eur. J. Oncol. 2004, 9, 169–175. [Google Scholar]
- Comba, P.; Gianfagna, A.; Paoletti, L. Pleural Mesothelioma Cases in Biancavilla are Related to a New Fluoro-Edenite Fibrous Amphibole. Arch. Environ. Health Int. J. 2003, 58, 229–232. [Google Scholar] [CrossRef] [PubMed]
- Biggeri, A.; Pasetto, R.; Belli, S.; Bruno, C.; Di Maria, G.; Mastrantonio, M.; Trinca, S.; Uccelli, R.; Comba, P. Mortality from chronic obstructive pulmonary disease and pleural mesothelioma in an area contamined by natural fibre (fluoro-edenite). Scand. J. Work Environ. Health 2004, 30, 249–252. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gianfagna, A.; Ballirano, P.; Bellatreccia, F.; Bruni, B.; Paoletti, L.; Oberti, R. Characterization of amphibole fibres linked to mesothelioma in the area of Biancavilla, Eastern Sicily, Italy. Miner. Mag. 2003, 67, 1221–1229. [Google Scholar] [CrossRef]
- Grosse, Y.; Loomis, D.; Guyton, K.Z.; Lauby-Secretan, B.; El Ghissassi, F.; Bouvard, V.; Benbrahim-Tallaa, L.; Guha, N.; Scoccianti, C.; Mattock, H.; et al. Carcinogenicity of fluoro-edenite, silicon carbide fibres and whiskers, and carbon nanotubes. Lancet Oncol. 2014, 15, 1427–1428. [Google Scholar] [CrossRef]
- Ledda, C.; Loreto, C.; Matera, S.; Massimino, N.; Cannizzaro, E.; Musumeci, A.; Migliore, M.; Fenga, C.; Pomara, C.; Rapisarda, V. Early effects of fluoro-edenite: Correlation between IL-18 serum levels and pleural and parenchymal abnormalities. Future Oncol. 2016, 12, 59–62. [Google Scholar] [CrossRef]
- Ledda, C.; Rapisarda, V. Malignant Pleural Mesothelioma: The Need to Move from Research to Clinical Practice. Arch. Med Res. 2016, 47, 407. [Google Scholar] [CrossRef]
- Ledda, C.; Pomara, C.; Bracci, M.; Mangano, D.; Ricceri, V.; Musumeci, A.; Ferrante, M.; Musumeci, G.; Loreto, C.; Fenga, C.; et al. Natural carcinogenic fiber and pleural plaques assessment in a general population: A cross-sectional study. Environ. Res. 2016, 150, 23–29. [Google Scholar] [CrossRef] [PubMed]
- Ledda, C.; Loreto, C.; Pomara, C.; Rapisarda, G.; Fiore, M.; Ferrante, M.; Bracci, M.; Santarelli, L.; Fenga, C.; Rapisarda, V. Sheep lymph-nodes as a biological indicator of environmental exposure to fluoro-edenite. Environ. Res. 2016, 147, 97–101. [Google Scholar] [CrossRef] [PubMed]
- Ledda, C.; Costa, C.; Matera, S.; Puglisi, B.; Costanzo, V.; Bracci, M.; Fenga, C.; Rapisarda, V.; Loreto, C. Immuno-modulatory effects in workers exposed to naturally occurring asbestos fibers. Mol. Med. Rep. 2017, 15, 3372–3378. [Google Scholar] [CrossRef]
- Ledda, C.; Caltabiano, R.; Loreto, C.; Cinà, D.; Senia, P.; Musumeci, A.; Ricceri, V.; Pomara, C.; Rapisarda, V. Prevalence of anti-nuclear autoantibodies in subjects exposed to natural asbestiform fibers: A cross-sectional study. J. Immunotoxicol. 2017, 15, 24–28. [Google Scholar] [CrossRef]
- Martinez, G.; Loreto, C.; Rapisarda, V.; Musumeci, G.; Valentino, M.; Carnazza, M.L. Effects of exposure to fluo-ro-edenite fibre pollution on the respiratory system: An in vivo model. Histol. Histopathol. 2006, 21, 595–601. [Google Scholar] [PubMed]
- Rapisarda, V.; Loreto, C.; Castorina, S.; Romano, G.; Garozzo, S.F.; Musumeci, A.; Migliore, M.; Avola, R.; Cinà, D.; Pomara, C.; et al. Occupational exposure to fluoro-edenite and prevalence of anti-nuclear autoantibodies. Future Oncol. 2018, 14, 59–62. [Google Scholar] [CrossRef]
- Paoletti, L.; Batisti, D.; Bruno, C.; Di Paola, M.; Gianfagna, A.; Mastrantonio, M.; Nesti, M.; Comba, P. Unusually High Incidence of Malignant Pleural Mesothelioma in a Town of Eastern Sicily: An Epidemiological and Environmental Study. Arch. Environ. Health Int. J. 2000, 55, 392–398. [Google Scholar] [CrossRef]
- Di Paola, M.; Mastrantonio, M.; Carboni, M.; Belli, S.; Grignoli, M.; Comba, P.; Nesti, M. Mortality from malignant pleural neoplasms in Italy in the years 1988–1992. Rapporti ISTISAN 1996, 96, 1–30. [Google Scholar]
- Fazzo, L.; De Santis, M.; Minelli, G.; Bruno, C.; Zona, A.; Marinaccio, A.; Conti, S.; Comba, P. Pleural mesothelioma mortality and asbestos exposure mapping in Italy. Am. J. Ind. Med. 2011, 55, 11–24. [Google Scholar] [CrossRef] [PubMed]
- Salle, F.G.; Churg, A.; Roggli, V.; Travis, W.D. The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification. J. Thorac. Oncol. 2016, 11, 142–154. [Google Scholar] [CrossRef] [Green Version]
- Rapisarda, V.; Ledda, C.; Ricceri, V.; Arena, F.; Musumeci, A.; Marconi, A.; Fago, L.; Bracci, M.; Santarelli, L.; Ferrante, M. Detection of pleural plaques in workers exposed to inhalation of natural fluoro-edenite fibres. Oncol. Lett. 2015, 9, 2046–2052. [Google Scholar] [CrossRef] [PubMed]
- Travaglione, S.; Bruni, B.; Falzano, L.; Paoletti, L.; Fiorentini, C. Effects of the new-identified amphibole fluoro-edenite in lung epithelial cells. Toxicol. In Vitro 2003, 17, 547–552. [Google Scholar] [CrossRef]
- Ledda, C.; Lombardo, C.; Tendi, E.A.; Hagnäs, M.; Paravizzini, G.; Filetti, V.; Rapisarda, V. Pathway of Inflammation due to Asbestiform Fiber “Fluoro-edenite” Exposure: An Update. Curr. Respir. Med. Rev. 2020, 16, 73–75. [Google Scholar] [CrossRef]
- Loreto, C.; Caltabiano, R.; Graziano, A.C.E.; Castorina, S.; Lombardo, C.; Filetti, V.; Vitale, E.; Rapisarda, G.; Cardile, V.; Ledda, C.; et al. Defense and protection mechanisms in lung exposed to asbestiform fiber: The role of macrophage migration inhibitory factor and heme oxygenase-1. Eur. J. Histochem. 2020, 64, 3073. [Google Scholar] [CrossRef]
- Yang, H.; Testa, J.R.; Carbone, M. Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr. Treat. Options Oncol. 2008, 9, 147–157. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Micolucci, L.; Rippo, M.R.; Olivieri, F.; Procopio, A.D. Progress of research on microRNAs with diagnostic value in asbestos exposure: A call for method standardization. Biosci. Trends 2017, 11, 105–109. [Google Scholar] [CrossRef]
- Caltabiano, R.; Loreto, C.; Vitale, E.; Matera, S.; Miozzi, E.; Migliore, M.; Angelico, G.; Tumino, R.; Ledda, C.; Rapisarda, V. Fibulin-3 immunoexpression in malignant mesothelioma due to fluoro-edenite: A preliminary report. Future Oncol. 2018, 14, 53–57. [Google Scholar] [CrossRef]
- Angelico, G.; Caltabiano, R.; Loreto, C.; Ieni, A.; Tuccari, G.; Ledda, C.; Rapisarda, V. Immunohistochemical Expression of Aquaporin-1 in Fluoro-Edenite-Induced Malignant Mesothelioma: A Preliminary Report. Int. J. Mol. Sci. 2018, 19, 685. [Google Scholar] [CrossRef] [Green Version]
- Arnold, D.T.; Maskell, N.A. Biomarkers in mesothelioma. Ann. Clin. Biochem. Int. J. Lab. Med. 2017, 55, 49–58. [Google Scholar] [CrossRef] [Green Version]
- Wu, T.; Zhang, W.; Yang, G.; Li, H.; Chen, Q.; Song, R.; Zhao, L. HMGB1 overexpression as a prognostic factor for survival in cancer: A meta-analysis and systematic review. Oncotarget 2016, 7, 50417–50427. [Google Scholar] [CrossRef] [Green Version]
- Loreto, C.; Lombardo, C.; Caltabiano, R.; Ledda, C.; Hagnäs, M.; Filetti, V.; Rapisarda, V. An in vivo immunohisto-chemical study on MacroH2A.1 in lung and lymph-node tissues exposed to an asbestiform fiber. Curr. Mol. Med. 2020, 20, 653–660. [Google Scholar] [CrossRef]
- Chen, Z.; Gaudino, G.; Pass, H.I.; Carbone, M.; Yang, H. Diagnostic and prognostic biomarkers for malignant meso-thelioma: An update. Transl. Lung Cancer Res. 2017, 6, 259–269. [Google Scholar] [CrossRef] [Green Version]
- Creaney, J.; Sneddon, S.; Dick, I.M.; Dare, H.; Boudville, N.; Musk, A.W.; Skates, S.J.; Robinson, B.W. Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for meso-thelioma in pleural effusions and serum. Dis. Markers 2013, 35, 119–127. [Google Scholar] [CrossRef] [Green Version]
- Creaney, J.; Dick, I.M.; Meniawy, T.; Leong, S.L.; Leon, J.S.; Demelker, Y.; Segal, A.; Musk, A.W.; Lee, Y.C.G.; Skates, S.J.; et al. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. Thorax 2014, 69, 895–902. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cui, A.; Jin, X.-G.; Zhai, K.; Tong, Z.-H.; Shi, H.-Z. Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: Updated meta-analysis. BMJ Open 2014, 4, e004145. [Google Scholar] [CrossRef]
- Polo, A.; Crispo, A.; Cerino, P.; Falzone, L.; Candido, S.; Giudice, A.; De Petro, G.; Ciliberto, G.; Montella, M.; Budillon, A.; et al. Environment and bladder cancer: Molecular analysis by interaction networks. Oncotarget 2017, 8, 65240–65252. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vrijens, K.; Bollati, V.; Nawrot, T.S. MicroRNAs as Potential Signatures of Environmental Exposure or Effect: A Systematic Review. Environ. Health Perspect. 2015, 123, 399–411. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Reid, G. MicroRNAs in mesothelioma: From tumour suppressors and biomarkers to therapeutic targets. J. Thorac. Dis. 2015, 7, 1031–1040. [Google Scholar]
- Falzone, L.; Scola, L.; Zanghì, A.; Biondi, A.; Di Cataldo, A.; Libra, M.; Candido, S. Integrated analysis of colorectal cancer microRNA datasets: Identification of microRNAs associated with tumor development. Aging 2018, 10, 1000–1014. [Google Scholar] [CrossRef]
- Falzone, L.; Lupo, G.; La Rosa, G.R.M.; Crimi, S.; Anfuso, C.D.; Salemi, R.; Rapisarda, E.; Libra, M.; Candido, S. Identification of Novel MicroRNAs and Their Diagnostic and Prognostic Significance in Oral Cancer. Cancers 2019, 11, 610. [Google Scholar] [CrossRef] [Green Version]
- Micolucci, L.; Akhtar, M.M.; Olivieri, F.; Rippo, M.R.; Procopio, A.D. Diagnostic value of microRNAs in asbestos ex-posure and malignant mesothelioma: Systematic review and qualitative meta-analysis. Oncotarget 2016, 7, 58606–58637. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ledda, C.; Senia, P.; Rapisarda, V. Biomarkers for Early Diagnosis and Prognosis of Malignant Pleural Mesothelioma: The Quest Goes on. Cancers 2018, 10, 203. [Google Scholar] [CrossRef] [Green Version]
- Filetti, V.; Falzone, L.; Rapisarda, V.; Caltabiano, R.; Graziano, A.C.E.; Ledda, C.; Loreto, C. Modulation of microRNA expression levels after naturally occurring asbestiform fibers exposure as a diagnostic biomarker of mesothelial neoplastic transformation. Ecotoxicol. Environ. Saf. 2020, 198, 110640. [Google Scholar] [CrossRef] [PubMed]
- Crimi, S.; Falzone, L.; Gattuso, G.; Grillo, C.M.; Candido, S.; Bianchi, A.; Libra, M. Droplet Digital PCR Analysis of Liquid Biopsy Samples Unveils the Diagnostic Role of hsa-miR-133a-3p and hsa-miR-375-3p in Oral Cancer. Biology 2020, 9, 379. [Google Scholar] [CrossRef] [PubMed]
- Salemi, R.; Falzone, L.; Madonna, G.; Polesel, J.; Cinà, D.; Mallardo, D.; Ascierto, P.A.; Libra, M.; Candido, S. MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients with BRAFV600E Mutation Detected in Circulating-Free DNA. Front. Pharmacol. 2018, 9, 856. [Google Scholar] [CrossRef]
- Shirdel, E.A.; Xie, W.; Mak, T.W.; Jurisica, I. NAViGaTing the Micronome—Using Multiple MicroRNA Prediction Databases to Identify Signalling Pathway-Associated MicroRNAs. PLoS ONE 2011, 6, e17429. [Google Scholar] [CrossRef] [Green Version]
- Tokar, T.; Pastrello, C.; Rossos, A.E.M.; Abovsky, M.; Hauschild, A.-C.; Tsay, M.; Lu, R.; Jurisica, I. mirDIP 4.1—integrative database of human microRNA target predictions. Nucleic Acids Res. 2018, 46, D360–D370. [Google Scholar] [CrossRef]
- Goldman, M.J.; Craft, B.; Hastie, M.; Repečka, K.; McDade, F.; Kamath, A.; Banerjee, A.; Luo, Y.; Rogers, D.; Brooks, A.N.; et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat. Biotechnol. 2020, 38, 675–678. [Google Scholar] [CrossRef]
- Ramírez-Salazar, E.G.; Salinas-Silva, L.C.; Vázquez-Manríquez, M.E.; Gayosso-Gómez, L.V.; Negrete-Garcia, M.C.; Ramírez-Rodriguez, S.L.; Chávez, R.; Zenteno, E.; Santillán, P.; Kelly-García, J.; et al. Analysis of microRNA expression signatures in malignant pleural mesothelioma, pleural inflammation, and atypical mesothelial hyperplasia reveals common predictive tumorigenesis-related targets. Exp. Mol. Pathol. 2014, 97, 375–385. [Google Scholar] [CrossRef]
- Lu, H.M.; Yi, W.W.; Ma, Y.S.; Wu, W.; Yu, F.; Fan, H.W.; Lv, Z.W.; Yang, H.Q.; Chang, Z.Y.; Zhang, C.; et al. Prognostic implications of decreased microRNA-101-3p expression in patients with non-small cell lung cancer. Oncol. Lett. 2018, 16, 7048–7056. [Google Scholar] [CrossRef] [Green Version]
- Yao, Z.-S.; Li, C.; Liang, D.; Jiang, X.-B.; Tang, J.-J.; Ye, L.-Q.; Yuan, K.; Ren, H.; Yang, Z.-D.; Jin, D.-X.; et al. Diagnostic and prognostic implications of serum miR-101 in osteosarcoma. Cancer Biomark. 2018, 22, 127–133. [Google Scholar] [CrossRef]
- Hu, J.; Wu, C.; Zhao, X.; Liu, C. The prognostic value of decreased miR-101 in various cancers: A meta-analysis of 12 studies. OncoTargets Ther. 2017, 10, 3709–3718. [Google Scholar] [CrossRef] [Green Version]
- Falzone, L.; Grimaldi, M.; Celentano, E.; Augustin, L.S.A.; Libra, M. Identification of Modulated MicroRNAs Associated with Breast Cancer, Diet, and Physical Activity. Cancers 2020, 12, 2555. [Google Scholar] [CrossRef]
- Candido, S.; Lupo, G.; Pennisi, M.; Basile, M.S.; Anfuso, C.D.; Petralia, M.C.; Gattuso, G.; Vivarelli, S.; Spandidos, D.A.; Libra, M.; et al. The analysis of miRNA expression profiling datasets reveals inverse microRNA patterns in glioblastoma and Alzheimer’s disease. Oncol. Rep. 2019, 42, 911–922. [Google Scholar] [CrossRef] [Green Version]
- Hafsi, S.; Candido, S.; Maestro, R.; Falzone, L.; Soua, Z.; Bonavida, B.; Spandidos, D.A.; Libra, M. Correlation between the overexpression of Yin Yang 1 and the expression levels of miRNAs in Burkitt’s lymphoma: A computational study. Oncol. Lett. 2016, 11, 1021–1025. [Google Scholar] [CrossRef] [Green Version]
- Ross, J.S.; Gay, L.M.; Sokol, E.; Elvin, J.A.; Vergilio, J.-A.; Suh, J.; Ramkissoon, S.H.; Daniel, S.; Severson, E.A.; Killian, J.K.; et al. PBRM1 genomic alterations in mesothelioma: Potential predictor of immunotherapy efficacy. J. Clin. Oncol. 2018, 36, 8562. [Google Scholar] [CrossRef]
- Zhang, J.; Zhou, N.; Lin, A.; Luo, P.; Chen, X.; Deng, H.; Kang, S.; Guo, L.; Zhu, W.; Zhang, J. ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer. Cancer Immunol. Immunother. 2021, 70, 137–151. [Google Scholar] [CrossRef] [PubMed]
- Kim, J.H.; Kim, H.S.; Kim, B.J. Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review. Oncotarget 2017, 8, 48248–48252. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Marazioti, A.; Blanquart, C.; Krontira, A.C.; Pepe, M.A.A.; Hackl, C.M.; Iliopoulou, M.; Lamort, A.S.; Koch, I.; Lindner, M.; Hatz, R.A.; et al. KRAS signalling in malignant pleural mesothelioma. bioRxiv 2020. [Google Scholar]
- Cavallari, I.; Urso, L.; Sharova, E.; Pasello, G.; Ciminale, V. Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives. Front. Oncol. 2019, 9, 740. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sato, H.; Soh, J.; Aoe, K.; Fujimoto, N.; Tanaka, S.; Namba, K.; Torigoe, H.; Shien, K.; Yamamoto, H.; Tomida, S.; et al. Droplet digital PCR as a novel system for the detection of microRNA-34b/c methylation in circulating DNA in malignant pleural mesothelioma. Int. J. Oncol. 2019, 54, 2139–2148. [Google Scholar] [CrossRef] [PubMed]
- Tuaeva, N.O.; Falzone, L.; Porozov, Y.B.; Nosyrev, A.E.; Trukhan, V.M.; Kovatsi, L.; Spandidos, D.A.; Drakoulis, N.; Kalogeraki, A.; Mamoulakis, C.; et al. Translational Application of Circulating DNA in Oncology: Review of the Last Decades Achievements. Cells 2019, 8, 1251. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tomasetti, M.; Amati, M.; Neuzil, J.; Santarelli, L. Circulating epigenetic biomarkers in lung malignancies: From early diagnosis to therapy. Lung Cancer 2017, 107, 65–72. [Google Scholar] [CrossRef]
Age Range (Years) | Mean Age (Years) | Gender | Pathologies | Pathological Subtype | Survival Time Range (Days) | Mean Survival Time (Days) | |
---|---|---|---|---|---|---|---|
Cases (n = 10) | 50–93 | 68.4 ± 13.9 | 60% men, 40% women | 100% malignant mesothelioma | 60% epithelioid, 10% sarcomatoid, 30% biphasic | 45–1800 | 579 ± 525 |
Controls (n = 8) | 15–76 | 44 ± 25.5 | 100% men | 37.5% pulmonary emphysema, 62.5% pleurisy |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Filetti, V.; Loreto, C.; Falzone, L.; Lombardo, C.; Cannizzaro, E.; Castorina, S.; Ledda, C.; Rapisarda, V. Diagnostic and Prognostic Value of Three microRNAs in Environmental Asbestiform Fibers-Associated Malignant Mesothelioma. J. Pers. Med. 2021, 11, 1205. https://doi.org/10.3390/jpm11111205
Filetti V, Loreto C, Falzone L, Lombardo C, Cannizzaro E, Castorina S, Ledda C, Rapisarda V. Diagnostic and Prognostic Value of Three microRNAs in Environmental Asbestiform Fibers-Associated Malignant Mesothelioma. Journal of Personalized Medicine. 2021; 11(11):1205. https://doi.org/10.3390/jpm11111205
Chicago/Turabian StyleFiletti, Veronica, Carla Loreto, Luca Falzone, Claudia Lombardo, Emanuele Cannizzaro, Sergio Castorina, Caterina Ledda, and Venerando Rapisarda. 2021. "Diagnostic and Prognostic Value of Three microRNAs in Environmental Asbestiform Fibers-Associated Malignant Mesothelioma" Journal of Personalized Medicine 11, no. 11: 1205. https://doi.org/10.3390/jpm11111205